OncoMatch/Clinical Trials/NCT06877299
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
Is NCT06877299 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT) for lung cancer.
Treatment: Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT) — This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Patients with known EGFR-sensitive mutations ... [are excluded]
Required: ALK fusion
Patients with known ... ALK fusion [are excluded]
Required: PD-L1 (CD274) expression testing required (testing required; no eligibility threshold specified)
tumor tissue or cell wax blocks that meet quality control standards for PD-L1 expression testing
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T cell receptors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify